• Home
  • NEW DAY MEDICINE
  • 4 (90) 2026
  • 55 -4 (90) 2026 - Rizaev J.A., Agababyan L.R. - MEDICAL AND SOCIAL DETERMINANTS AND BARRIERS IN THE TREATMENT OF CLIMACTERIC SYNDROME: RESULTS OF A CROSS-SECTIONAL STUDY

55 -4 (90) 2026 - Rizaev J.A., Agababyan L.R. - MEDICAL AND SOCIAL DETERMINANTS AND BARRIERS IN THE TREATMENT OF CLIMACTERIC SYNDROME: RESULTS OF A CROSS-SECTIONAL STUDY

MEDICAL AND SOCIAL DETERMINANTS AND BARRIERS IN THE TREATMENT OF CLIMACTERIC SYNDROME: RESULTS OF A CROSS-SECTIONAL STUDY

Rizaev J.A. - Samarkand State Medical University

Agababyan L.R. - Samarkand State Medical University

Khalmuratova K.Zh. - Samarkand State Medical University

Resume

Background: The menopausal transition period is often accompanied by a deterioration in women’s well-being and quality of life. Although the effectiveness of menopausal hormone therapy (MHT) has been confirmed by numerous studies, its utilization among patients remains low. The influence of organizational factors within healthcare systems and the level of medical awareness on women’s refusal of therapy in Central Asian countries has been insufficiently studied. Objective: To assess the medical and social determinants, the level of awareness, and indicators of access to healthcare among women during the menopausal transition. Materials and Methods: A cross-sectional study was conducted involving 451 women aged 46–67 years. A questionnaire was used to evaluate access to healthcare and the quality of communication with physicians. Statistical analysis included Pearson’s χ² test and Fisher’s exact test. Results: The integral index of organizational accessibility was 10.07±1.72 points (median 11), while the communication quality index was 4.74±0.78 points (median 5). Despite well-developed infrastructure, 80.2% of women had never consulted a physician previously. The main barrier was hormonophobia (36.4% of respondents). Only 36.0% had sufficient knowledge about MHT, and awareness was significantly associated with healthcare-seeking behavior (p < 0.001).

Keywords: menopause, climacteric syndrome, menopausal hormone therapy, access to medical care, hormonophobia.

First page

389

Last page

394

For citation:Rizaev J.A., Agababyan L.R., Khalmuratova K.Zh. - MEDICAL AND SOCIAL DETERMINANTS AND BARRIERS IN THE TREATMENT OF CLIMACTERIC SYNDROME: RESULTS OF A CROSS-SECTIONAL STUDY//New Day in Medicine 4(90)2026 389-394 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

  1. Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas. 2014 Nov;79(3):287-291. doi:10.1016/j.maturitas.2014.07.002.
  2. Augoulea A, Moros M, Lykeridou A, et al. Psychosomatic and vasomotor symptom changes during transition to menopause. Prz Menopauzalny. 2019 Jun;18(2):110-115.
  3. Barber K, Charles A, et al. Barriers to accessing effective treatment and support for menopausal symptoms: a qualitative study capturing the behaviours, beliefs and experiences of key stakeholders. Patient Prefer Adherence. 2023;17:2971-2980.
  4. Islam RM, Rana J, Katha S, et al. Menopause in low and middle-income countries: a scoping review of knowledge, symptoms and management. Climacteric. 2025;28(3):242–279.
  5. Panay N, Ang SB, Cheshire R, et al. Menopause and MHT in 2024: addressing the key controversies—an International Menopause Society White Paper. Climacteric. 2024;27(5):441-457. doi:10.1080/13697137.2024.2394950.
  6. Rodrigues MAH, Reis Z, Verona A, et al. Climacteric women's perspectives on menopause and hormone therapy: knowledge gaps, fears and the role of healthcare advice. PLoS One. 2024;19(4):e0312345. doi:10.1371/journal.pone.0312345.
  7. Raskin L, Boretti E, Douxfils J, et al. Patient preferences regarding menopausal symptoms and treatments: a systematic review of quantitative stated-preference studies. Patient. 2026.
  8. Rozenberg S, Panay N, Gambacciani M, et al. Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspective. Expert Rev Clin Pharmacol. 2023;16(6):507-517. doi:10.1080/17512433.2023.2201239.
  9. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028.
  10. Wang L, Zhang R, Yang Y, et al. Severity and factors of menopausal symptoms in middle-aged women in Gansu Province of China: a cross-sectional study. BMC Womens Health. 2021;21(1):405. doi:10.1186/s12905-021-01520-7.
  11. Zhang Y, Hu TT, Cheng YR, et al. Global, regional, and national burden of anxiety disorders during the perimenopause (1990–2021) and projections to 2035. BMC Womens Health. 2025;25:11. doi:10.1186/s12905-025-02811-2.
  12. Халмуратова К.Ж. Климактерический синдром в современных условиях (обзор литературы). Вестник фундаментальной и клинической медицины. 2025;6(20):1104–1106. doi:10.5281/zenodo.17933955.

    file

    download